Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial
Titel:
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial
Auteur:
Nanni, O. Amadori, D. Censi, A. De Rocca, A. Freschi, A. Bologna, A. Gianni, L. Rosetti, F. Amaducci, L. Cavanna, L. Foca, F. Sarti, S. Serra, P. Valmorri, L. Bruzzi, P. Corradengo, D. Gennari, A.